GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
This was the stock's second consecutive day of losses.
Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...
Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...
Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...
The stock's fall snapped an eight-day winning streak.
Zacks.com on MSN1d
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...
Gilead Sciences (NASDAQ:GILD) shares continued gains for the eighth straight session, as the stock was up 1.5% on Monday. The ...
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...
Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...
Morrow County Food Pantry co-directors Brenda Harden and Teresa Shipman were delighted with the contributions from Mount ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback